HC Wainwright Reaffirms Buy Rating for Synthetic Biologics (SYN)
Synthetic Biologics (NYSEAMERICAN:SYN)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Friday.
SYN has been the subject of a number of other research reports. Zacks Investment Research upgraded Synthetic Biologics from a “sell” rating to a “hold” rating in a research note on Saturday, February 24th. Griffin Securities downgraded Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $2.63.
Shares of Synthetic Biologics opened at $0.25 on Friday, Marketbeat Ratings reports. Synthetic Biologics has a one year low of $0.19 and a one year high of $1.05.
Institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC raised its holdings in Synthetic Biologics by 256.1% during the 4th quarter. Virtu Financial LLC now owns 299,577 shares of the company’s stock valued at $152,000 after acquiring an additional 215,440 shares during the period. Citadel Advisors LLC raised its holdings in Synthetic Biologics by 312.1% during the 4th quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock valued at $122,000 after acquiring an additional 183,120 shares during the period. 683 Capital Management LLC bought a new stake in Synthetic Biologics during the 4th quarter valued at $762,000. Finally, Blair William & Co. IL raised its holdings in Synthetic Biologics by 14.8% during the 1st quarter. Blair William & Co. IL now owns 1,980,857 shares of the company’s stock valued at $631,000 after acquiring an additional 255,096 shares during the period.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.